Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US45256X1037
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG007T9DYW9
IBRX
Immunitybio Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Immunitybio Inc
ISIN
US45256X1037
TICKER
IBRX
MIC
XNAS
REUTERS
IBRX.OQ
BLOOMBERG
IBRX US
Fri, 10.04.2026       ImmunityBio
US45256X1037

BENSALEM, Pa., April 10, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN IMMUNITYBIO, INC. (IBRX), CONTA...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.04.2026       ImmunityBio
US45256X1037

Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”), have until Tuesday, May 26, 2026 to seek appointment as lead plaintiff of the ImmunityBio class action lawsuit. Captioned Douglas v....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi p...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.04.2026       ImmunityBio
US45256X1037

Philadelphia, Pennsylvania--(Newsfile Corp. - April 10, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) ("ImmunityBio" or the "Company") on behalf of investors who purchased or acquired ImmunityBio shares during the period from January 19, 2026 through March 24, 2026...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       ImmunityBio
US45256X1037

SAN FRANCISCO, April 9, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       ImmunityBio
US45256X1037

Did you buy IBRX securities between January 19, 2026, and March 24, 2026?Affected IBRX Investor SummaryWho: ImmunityBio, Inc. (NASDAQ: IBRX)What: Securities fraud class action lawsuit filedClass Period: January 19, 2026 through March 24, 2026Deadline to Seek Lead Plaintiff Status: May 26, 2026Key Lawsuit Allegations: Material misstatements and/or...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities class...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       ImmunityBio
US45256X1037

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail a...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, announced today preliminary select operational results for the fiscal quarter ending March 31, 2026. ImmunityBio reported preliminary net product revenue of approximately $44.2 million during the three-month period ending March 31, 2026, with net product revenue growth in...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       ImmunityBio
US45256X1037

If you have suffered a loss on your ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 08.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.04.2026       ImmunityBio
US45256X1037

LOS ANGELES, April 8, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) have opportunity to lead the securities fraud class action lawsuit....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.04.2026       ImmunityBio
US45256X1037

SAN DIEGO, April 8, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, all dates inclusive (the "Class Period"), have until May 26, 2026 to seek appointment as lead plaintiff of the ImmunityBio c...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       ImmunityBio
US45256X1037

Institutional investors holding positions in ImmunityBio, Inc. (NASDAQ: IBRX) during the period January 19, 2026 through March 24, 2026 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Shares lost $1.98 per share, a 21% decline, after an FDA Warning Letter exposed allegedly false promotional claims about the C...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       ImmunityBio
US45256X1037

SAN FRANCISCO, April 7, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 7, 2026) - Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.Should You Join The ImmunityBio Cl...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       ImmunityBio
US45256X1037

NEW YORK, April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). Shareholders who purchased shares of IBRX during the class period listed are encouraged to con...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       ImmunityBio
US45256X1037

NEW YORK, April 7, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (th...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced it has submitted a comprehensive response to the U.S. Food and Drug Administration (FDA) Office of Prescription Drug Promotion (OPDP) regarding issues raised on March 13, 2026 related to a television advertisement and a podcast. The company addressed the co...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 06.04.2026       ImmunityBio
US45256X1037

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Sharehold...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       ImmunityBio
US45256X1037

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sun, 05.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities class acti...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi p...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       ImmunityBio
US45256X1037

SAN DIEGO, April 3, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, inclusive (the "Class Period"), have until May 26, 2026 to seek appointment as lead plaintiff of the Immunit...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       ImmunityBio
US45256X1037

SAN FRANCISCO, April 3, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       ImmunityBio
US45256X1037

NEW ORLEANS, April 3, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) ("ImmunityBio" or the "Company"), if they purchased or otherwise acquired the Company...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities class...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       ImmunityBio
US45256X1037

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 26, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) securities between January 19, 2026 and March 24, 2026, inclusive (the “C...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       ImmunityBio
US45256X1037

Did you buy IBRX securities between January 19, 2026, and March 24, 2026?Affected IBRX Investor SummaryWho: ImmunityBio, Inc. (NASDAQ: IBRX)What: Securities fraud class action lawsuit filedClass Period: January 19, 2026 through March 24, 2026Deadline to Seek Lead Plaintiff Status: May 26, 2026Key Lawsuit Allegations: Material misstatements and/or...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       ImmunityBio
US45256X1037

LOS ANGELES, April 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Sharehold...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       ImmunityBio
US45256X1037

LOS ANGELES, April 3, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities class...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       ImmunityBio
US45256X1037

Law Offices of Howard G. Smith reminds investors of the upcoming May 26, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”).IF YOU ARE AN INVESTOR...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       ImmunityBio
US45256X1037

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       ImmunityBio
US45256X1037

SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       ImmunityBio
US45256X1037

NEW YORK, April 1, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       ImmunityBio
US45256X1037

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) securities between January 19, 2026 and March 24, 2026, inclusive (...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       ImmunityBio
US45256X1037

Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRANEW YORK, April 1, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ImmunityBio, Inc. (NASDAQ: IBRX) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between January 19, 2026 and March 24, 2026. IBRX shares fell $1...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       ImmunityBio
US45256X1037

Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against ImmunityBio, Inc. (ImmunityBio) (NASDAQ: IBRX) on behalf of those who purchased or acquired ImmunityBio securities between January 19, 2026, and March 2...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       ImmunityBio
US45256X1037

LOS ANGELES, April 1, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - March 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"). A class action lawsuit ha...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       ImmunityBio
US45256X1037

Institutional investors holding positions in ImmunityBio, Inc. (NASDAQ: IBRX) during the period January 19, 2026 through March 24, 2026 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Shares lost $1.98 per share, a 21% decline, after an FDA Warning Letter exposed allegedly false promotional claims about the C...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       ImmunityBio
US45256X1037

SAN DIEGO, March 31, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), have until May 26, 2026 to seek appointment as lead plaintiff of the ImmunityBio...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       ImmunityBio
US45256X1037

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). ImmunityBio investors have until May 26, 2026 t...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       ImmunityBio
US45256X1037

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). ImmunityBio investors have until May 26, 2026 to file a lead plaintiff moti...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - March 31, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, inclus...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       ImmunityBio
US45256X1037

NEW YORK, March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). Shareholders who purchased shares of IBRX during the class period listed are encouraged to co...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced it has secured $75 million in non-dilutive financing under its existing Royalty Interest Purchase Agreement (RIPA) with Oberland Capital, increasing the total committed capital under the Agreement to $375 million. The amended agreemen...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink